Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00428792
First received: January 29, 2007
Last updated: April 11, 2011
Last verified: April 2011
Results First Received: January 6, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Methylphenidate 20 mg long-acting capsules

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Very Light Breakfast (VLB) Then Standard Breakfast (SB) Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 20 mg or 40 mg capsules of methylphenidate once daily based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
Standard Breakfast (SB) Then Very Light Breakfast (VLB) Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 20 mg or 40 mg capsules of methylphenidate once daily based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.

Participant Flow:   Overall Study
    Very Light Breakfast (VLB) Then Standard Breakfast (SB)     Standard Breakfast (SB) Then Very Light Breakfast (VLB)  
STARTED     80     70  
COMPLETED     79 [1]   66 [1]
NOT COMPLETED     1     4  
Lack of Efficacy                 1                 3  
Lost to Follow-up                 0                 1  
[1] Information is not available during which cross-over period patients discontinued.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Very Light Breakfast (VLB) Then Standard Breakfast (SB) Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 20 mg or 40 mg capsules of methylphenidate once daily based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
Standard Breakfast (SB) Then Very Light Breakfast (VLB) Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 20 mg or 40 mg capsules of methylphenidate once daily based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
Total Total of all reporting groups

Baseline Measures
    Very Light Breakfast (VLB) Then Standard Breakfast (SB)     Standard Breakfast (SB) Then Very Light Breakfast (VLB)     Total  
Number of Participants  
[units: participants]
  80     70     150  
Age [1]
[units: years]
Mean ± Standard Deviation
  9.6  ± 1.6     9.7  ± 1.5     9.7  ± 1.6  
Gender [1]
[units: participants]
     
Female     25     13     38  
Male     55     57     112  
[1] Safety Population



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Intent-to-Treat (ITT) Population   [ Time Frame: Friday of each of the 2 treatment weeks ]

2.  Primary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Teacher Rating in the Per Protocol (PP) Population   [ Time Frame: Friday of each of the 2 treatment weeks ]

3.  Secondary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Attention Deficit Subscale Teacher Rating   [ Time Frame: Friday of each of the 2 treatment weeks ]

4.  Secondary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Hyperactivity Subscale Teacher Rating   [ Time Frame: Friday of each of the 2 treatment weeks ]

5.  Secondary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Impulsiveness Subscale Teacher Rating   [ Time Frame: Friday of each of the 2 treatment weeks ]

6.  Secondary:   Fremdbeurteilungsbogen für Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen (FBB-AHDS) Parent Rating   [ Time Frame: Saturday of each of the 2 treatment weeks ]

7.  Secondary:   10-Minute Math Test – Problems Attempted   [ Time Frame: Saturday of each of the 2 treatment weeks ]

8.  Secondary:   10-Minute Math Test – Problems Solved   [ Time Frame: Saturday of each of the 2 treatment weeks ]

9.  Secondary:   Clinical Global Impression Severity (CGI-S) Scale Score – Physician Rating of Severity   [ Time Frame: Saturday of each of the 2 treatment weeks ]

10.  Secondary:   Clinical Global Impression (CGI-I) Scale Score – Physician Rating of Improvement (Change in State)   [ Time Frame: Saturday of each of the 2 treatment weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862 778-8300


No publications provided


Responsible Party: External Affairs, Novartis
ClinicalTrials.gov Identifier: NCT00428792     History of Changes
Other Study ID Numbers: CRIT124DDE04
Study First Received: January 29, 2007
Results First Received: January 6, 2011
Last Updated: April 11, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices